Who Can Prescribe Buprenorphine-Naloxone for Kratom Withdrawal
Any DEA-registered healthcare provider can prescribe buprenorphine-naloxone for kratom withdrawal without special training or waivers as of 2023. 1
Current Regulatory Framework (2023 DEA Changes)
The prescribing landscape for buprenorphine fundamentally changed in early 2023:
- No X-waiver required: Special training and the DEA "X-waiver" are no longer required to prescribe any buprenorphine formulation for either pain or opioid use disorder (OUD) 1
- Only standard DEA registration needed: Any physician, nurse practitioner, or physician assistant with standard DEA registration can prescribe buprenorphine 1
- No patient caps: There are no longer DEA limits on the number of patients a prescriber may treat 1
- State laws may still apply: Some state regulations limiting buprenorphine prescription may still be in effect, so check local requirements 1
Historical Context (Pre-2023)
Prior to 2023, the Drug Addiction Treatment Act of 2000 (DATA 2000) required physicians to complete an 8-hour training course and obtain an X-waiver to prescribe buprenorphine for OUD 2, 3. This created significant barriers, with less than 4% of prescribers obtaining waivers 4. These restrictions no longer exist.
Emergency Department Exception
Even before the 2023 changes, any DEA-licensed physician could administer (but not prescribe) buprenorphine in the ED for withdrawal symptoms with these restrictions 2:
- Not more than one day's medication may be administered at one time
- Treatment may not exceed 72 hours
- The 72-hour period cannot be renewed or extended
- Must arrange for patient referral for treatment
Practical Considerations for Kratom Withdrawal
Kratom withdrawal can be effectively managed with buprenorphine-naloxone, as demonstrated in multiple case reports 5, 6, 7, 8. The evidence shows:
- Low-dose sublingual buprenorphine-naloxone (typically 8 mg/2 mg daily) achieves complete abstinence within 3 weeks 5
- Home induction via telehealth has been successful 8
- Maintenance dosages vary significantly between patients despite similar kratom use patterns 8
Recommended Actions
While any DEA-registered provider can now prescribe:
- The FDA strongly encourages completing a REMS-compliant education program when prescribing buprenorphine products 1
- Consultation with pain or palliative care specialists is recommended for complex cases 1
- Providers should coordinate with mental health clinicians when co-existing psychiatric conditions are present, as kratom users often have underlying anxiety, depression, or OCD 5
Critical Caveat
Buprenorphine reduces morbidity and mortality in patients with OUD 1, making access to prescribers essential. The removal of the X-waiver requirement was specifically designed to address the treatment gap where only 37,000 physicians (less than 4% of prescribers) were waivered as of 2016 4.